Danaher Corporation $DHR Stock: Orca Wealth Management LLC Boosts Stake

Orca Wealth Management LLC grew its position in shares of Danaher Corporation (NYSE:DHR) by 159.3% during the third quarter, HoldingsChannel.com reports. The firm owned 7,164 shares of the conglomerate’s stock after purchasing an additional 4,401 shares during the period. Orca Wealth Management LLC’s holdings in Danaher were worth $1,587,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Triumph Capital Management lifted its holdings in shares of Danaher by 409.6% during the third quarter. Triumph Capital Management now owns 846 shares of the conglomerate’s stock worth $187,000 after purchasing an additional 680 shares during the period. Consilium Wealth Advisory LLC bought a new stake in shares of Danaher in the third quarter worth $580,000. Investment Planning Advisors Inc. acquired a new stake in Danaher in the third quarter valued at $2,540,000. Adirondack Trust Co. increased its holdings in Danaher by 536.1% in the third quarter. Adirondack Trust Co. now owns 13,963 shares of the conglomerate’s stock valued at $3,094,000 after purchasing an additional 11,768 shares during the period. Finally, Three Magnolias Financial Advisors LLC acquired a new stake in Danaher in the third quarter valued at $939,000. 79.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday. Barclays increased their price target on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Stifel Nicolaus decreased their price target on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. TD Cowen raised their price objective on Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Guggenheim lifted their price objective on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Danaher Trading Up 0.8%

Shares of DHR stock traded up $1.81 during mid-day trading on Wednesday, hitting $224.65. The company’s stock had a trading volume of 3,595,884 shares, compared to its average volume of 4,457,645. The company has a market cap of $157.93 billion, a PE ratio of 39.90, a P/E/G ratio of 2.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company’s fifty day simple moving average is $212.92 and its 200-day simple moving average is $195.39. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the company earned $0.77 EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, equities research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.